TAK-981 induces IFN1s, activating innate immune cells and leading to enhanced antibody-dependent effector functions for improved tumor control. TAK-981 treatment inhibits sumoylation, leading to the release of IFN1s. IFN1s then cause activation of macrophages and NK cells, increasing expression of activating FCGRs on macrophages. Activation enhances macrophage phagocytosis and NK cell cytotoxicity against tumor cells, particularly in the presence of direct targeting therapeutic monoclonal antibodies such as rituximab. TAM, tumor-associated macrophage. Professional illustration by Somersault18:24.